Predicting the role of the pretreatment neutrophil to lymphocyte ratio in the survival of early triple-negative breast cancer patients

Journal of B.U.ON.

Volumn 20, Issue 6, 2015, Pages 1432-1439

  Bozkurt, Oktay ^a   Karaca, Halit ^a   Berk, Veli ^a   Inanc, Mevlude ^b   Duran, Ayse Ocak ^a   Ozaslan, Ersin ^a   Ucar, Mahmut ^a   Ozkan, Metin ^a  

^a ERCIYES UNIVERSITY   (Turkey)

^b Kayseri Training and Research Hospital   (Turkey)

Author keywords

Breast cancer; Lymphocyte; Neutrophil; Ratio; Survival; Triple negative

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CHI SQUARE TEST; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LABORATORY TEST; MAJOR CLINICAL STUDY; MASTECTOMY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; AGED; BLOOD; LYMPHOCYTE; MORTALITY; NEUTROPHIL;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOCYTES; MIDDLE AGED; NEUTROPHILS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84960083474     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Maegawa ROB, Tang SC Triple-negative breast cancer: unique biology and its management. Cancer Investig 2010; 28:878-883,
2. Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24:5652-5657.
3. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26:1275-1281.
4. Dent R, Trudeau M, Pritchard Kl et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13 (15 Pt 1):4429-4434.
5. Foulkes WD, Smith IE, Reis-Filho JS Triple-negative breast cancer. N Engl J Med 2010; 363:1938-1948.
6. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011; 16(Suppl 1):1-11.
7. Ismail-Khan R., Bui MM A review of triple-negative breast cancer. Cancer Control 2010; 17:173-176.
8. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-2767.
9. Pistelli M, Pagliacci A, Battelli N et al. Prognostic factors in early-stage triple-negative breast cancer: lesson and limits from clinical practice. Anticancer Res 2013; 33:2737-2742.
10. Zhou L, Li K, Luo Y et al. Novel prognostic markers for patients with triple-negative breast cancer. Hum Pathol 2013; 44:2180-2187.
11. Veer LJV't, Dai H, Van De Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-536.
12. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883-899.
13. Yildirim M, Yildiz M, Duman E., Goktas S, Kaya V. Prognostic importance of the nutritional status and systemic inflammatory response in non-small cell lung cancer. JBUON 2013; 18:728-732.
14. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009; 15:425-430.
15. Roxburgh CS, McMillan DC Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010; 6:149-163.
16. Vigano A, Bruera E, Jhangri G.S., Fields AL, Suarez-Almazor ME. Clinical survival predictors in patients with advanced cancer. Arch Intern Med 2000; 160:861-868.
17. Gomez D, Farid S, Malik HZ et al. Preoperative neutrophil-to-lymphocyte ratio as prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 2008; 32:1757-1762.
18. Cetinkunar S, Guzel H, Emre Gokse I et al. High levels of platelet/lymphocyte ratio are associated with metastatic gastric caiicer. JBUON 2015; 20:78-83.
19. Guthrie GJ, Charles KA, Roxburgh C.S., Horgan PG, McMillan DC, Clarke SJ The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013; 88:218-230.
20. Tomita M, Shimizu T, Ayabe T., Yonei A, Onitsuka T. Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for nonsmall cell lung cancer. Anticancer Res 2011; 31:2995-2998.
21. Lee YY, Choi CH, Kim H.J., Kim TJ et al. Pretreatment neutrophil: lymphocyte ratio as a prognostic factor. in cervical carcinoma. Anticancer Res 2012; 32:1555-1561.
22. Sarraf KM, Belcher E, Raevsky E., Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009; 137:425-428.
23. Dirican A, Kucukzeybek Y, Somali et al. The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma. JBUON 2013; 18:413-419.
24. Kishi Y, Kopetz S, Chun Y.S., Palavecino M., Abdalla EK, Vauthey JN Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 2009; 16:614-622.
25. Ulas A, Avci N, Kos T et al. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab ? JBUON 2015; 20:714-722.
26. Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer 2013; 16:55-59.
27. Azab B, Bhatt VR, Phookan J et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting shortand long-term mortality in breast cancer patients. Ann Surg Oncol 2012; 19:217-224.
28. Azab B, Shah N, Radbel J et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol 2013; 30:432-434.
29. Petrie HT, Klassen LW, Kay HD Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol 1985; 134:230-234.
30. el-Hag A., Clark RA Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol 1987; 139:2406-2413.
31. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG02-98. J Clin Oncol 2013; 31:860-867.
32. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105:93-103.
33. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-545.
34. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28:105-113.
35. Canna K, McArdle PA, McMillan DC et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005; 92:651-654.
36. McCourt M, Wang JH, Sookhai S, Redmond HP Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg 1999; 134:1325-1331; discussion 1331-1322
37. Di Carlo E., Forni G, Musiani P. Neutrophils in the antitumoral immune response. Chem Immunol Allergy 2003; 83:182-203.
38. McCourt M, Wang JH, Sookhai S, Redmond HP Activated human neutrophils release hepatocyte growth factor/scatter factor. Eur J Surg Oncol 2001; 27:396-403.
39. Jablohska E, Kiluk M, Markiewicz W., Piotrowski L, Grabowska Z, Jablohski J. TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. Arch Immunol Ther Exp (Warsz) 2001; 49:63-69.
40. Schaider H, Oka M, Bogenrieder T et al. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 2003; 103:335-343.
41. Shamamian P, Schwartz JD, Pocock BJ et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 2001; 189:197-206.
42. Scapini P, Nesi L, Morini M et al. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol 2002; 168:5798-5804.
43. Brandau S, Moses K, Lang S. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins? Semin Cancer Biol 2013; 23:171-182.
44. Kazemfar K, Chen R, Nicholson K et al. Combined IL-8 and TGF-beta blockade efficiently prevents neutrophil infiltrates into an A549-cell tumor. Immunol Lett 2009; 122:26-29.
45. Tazzyman S, Barry ST, Ashton S et al. Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. Int J Cancer 2011; 129:847-858.
46. Pierce BL, Ballard-Barbash R, Bernstein L et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009; 27:3437-3444.
47. Al Murri A.M., Bartlett JM, Canney P.A., Doughty JC, Wilson C, McMillan DC Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 2006; 94:227-230.
48. Schmidt H, Bastholt L, Geertsen P et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 2005; 93:273-278.
49. Atzpodien J, Royston P, Wandert T., Reitz M. DGCIN - German cooperative renal carcinoma chemo-im-munotherapy trials group: metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003; 88:348-353.
50. Mahmoud SM, Paish EC, Powe DG et al. Tumor-infiltrating CD8 + lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29:1949-1955.
51. Pistelli M, De Lisa M, Ballatore Z et al. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer 2015, Mar 28; 15:195.
52. Bhat T, Teli S, Rijal J et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther 2013; 11:55-59.